The Penn FTD Center is a proud participant of a multi-center FTD clinical research study funded by the National Institutes of Health, the Tau Research Consortium and CBD Solutions.

The Four Repeat Tauopathy Neuroimaging Initiative (4RTNI) study is an observational, longitudinal study aiming to accelerate the development of new tests, treatments, and clinical trials for patients diagnosed with PSP and CBD.

This study is open and enrolling both patients and healthy controls who will be asked to come in for a baseline visit, a 6 month visit, a 12 month visit and a 24 month visit, depending on the diagnosis. Each visit lasts anywhere from 6 hours to 2-3 days. The longer visits can be broken up over several weeks.

This is enrolling patients at and combine research data from six research centers:

  • The University of California, San Francisco (UCSF);
  • The University of California, San Diego (UCSD);
  • Massachusetts General Hospital in Boson, Massachusetts;
  • The University of Toronto in Ontario, Canada;
  • The University of Pennsylvania in Philadelphia, Pennsylvania; and
  • The Mayo Clinic in Rochester, Minnesota.

Eligibility includes:

  • Being between 40-80 years old age
  • Having a study partner who can attend all study visits
  • Having a diagnosis of PSP, CBD, or naPPA
  • Having generally good health

Participation in 4RTNI may include:

  • Physical and cognitive examination by a neurologist
  • Blood sample
  • Magnetic resonance imaging (MRI) studies of the brain
  • PET imaging of the brain
  • Lumbar puncture for studies on cerebrospinal fluid
  • Cognitive testing
  • Retinal imaging
  • Measurements of the eyes
  • Completion of questionnaires by participant and study partner

For more information on participating, please contact Annabess Ehrhardt at the Penn FTD Center by telephone 215-349-5784 or email annabess.ehrhardt@pennmedicine.upenn.edu

More information on these national studies is available on ClinicalTrials.gov.

Advertisements